Adam Schoen, Brown Rudnick Partner and a Practice Group Leader of the Global Life Sciences Practice Group, authored “IP and Capital: Treat Patents as Strategic Business Assets and Build an IP Portfolio.” The piece was published in Pharmaceutical Executive magazine, a product of MJH Life Sciences. In the article, Adam discusses the flood of innovation over the past year and how that has brought to light many issues pertaining to intellectual property in the pharmaceutical industry.

Adam has worked in the life sciences industry for more than 20 years. He advises life sciences and medical device funds, companies, and academic institutions. Adam formerly served as a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and as a scientist at Millennium Pharmaceuticals Inc. Pharmaceutical Executive magazine offers pharmaceutical and biopharmaceutical executives with analysis of business, strategy, and government regulations. The magazine is part of MJH Life Sciences, a privately held, independent, full-service medical media company delivering health care news across multiple channels.

Read the complete article here.